Gingival crevicular fluid, serum levels of receptor activator of nuclear factor-kb ligand, osteoprotegerin, and interleukin-17 in patients with rheumatoid arthritis and osteoporosis and with periodontal disease

Journal of Periodontology

Volumn 84, Issue 11, 2013, Pages 1627-1637

  Gümüş, Pinar ^a   Buduneli, Eralp ^a   Başak, Biyikoǧlu ^a   Aksu, Kenan ^a   SaraÇ, Fulden ^a   Nile, Christopher ^b   Lappin, David ^b   Buduneli, Nurcan ^a  

^a EGE UNIVERSITY   (Turkey)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Gingival crevicular fluid; Interleukin 17; Osteoporosis; Osteoprotegerin; RANK ligand; Rheumatoid arthritis.

Indexed keywords

ALBUMINOID; AUTACOID; IL17A PROTEIN, HUMAN; IL17F PROTEIN, HUMAN; IL25 PROTEIN, HUMAN; INTERLEUKIN 17; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TNFSF11 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; FEMALE; GINGIVITIS; HUMAN; MALE; METABOLISM; MIDDLE AGED; OSTEOPOROSIS; PERIODONTAL DISEASE; PERIODONTAL POCKET; PERIODONTICS; PERIODONTITIS; RHEUMATOID ARTHRITIS;

ADULT; AGED; ALBUMINS; ARTHRITIS, RHEUMATOID; FEMALE; GINGIVAL CREVICULAR FLUID; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-17; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPROTEGERIN; PERIODONTAL ATTACHMENT LOSS; PERIODONTAL INDEX; PERIODONTAL POCKET; PERIODONTITIS; RANK LIGAND;

EID: 84888052359     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2013.120595     Document Type: Article

References (46)

1. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357.
2. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597-3602.
3. Quinn JMW, Horwood NJ, Elliott J, Gillespie MT, Martin TJ. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J Bone Miner Res 2000;15: 1459-1466.
4. Horwood NJ, Kartsogiannis V, Quinn JMW, Romas E, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999;265:144-150.
5. Lacey DL, Timms E, Tan H-L, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
6. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
7. Yao Z, Painter SL, Fanslow WC, et al. Human IL-17: A novel cytokine derived from T cells. J Immunol 1995;155:5483-5486.
8. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517.
9. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003;170:2655-2662.
10. Kramer JM, Gaffen SL. Interleukin-17: A new paradigm in inflammation, autoimmunity, and therapy. J Periodontol 2007;78:1083-1093.
11. Chang SH, Dong C. IL-17F: Regulation, signaling and function in inflammation. Cytokine 2009;46:7-11.
12. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008;28:454-467.
13. Dong C. Diversification of T-helper-cell lineages: Finding the family root of IL-17-producing cells. Nat Rev Immunol 2006;6:329-333.
14. Paradowska-Gorycka A, Wojtecka-Lukasik E, Trefler J, Wojciechowska B, Lacki JK, Maslinski S. Association between IL-17F gene polymorphisms and susceptibility to and severity of rheumatoid arthritis (RA). Scand J Immunol 2010;72:134-141.
15. Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res 2007;17:435-440.
16. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008; 226:57-79.
17. Monteleone G, Pallone F, Macdonald TT. Interleukin-25: A two-edged sword in the control of immune-inflammatory responses. Cytokine Growth Factor Rev 2010;21:471-475.
18. Pers JO, Saraux A, Pierre R, Youinou P. Anti-TNFalpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis. J Periodontol 2008;79:1645-1651.
19. Yavuzyilmaz E, Yamalik N, Calguner M, Ersoy F, Baykara M, Yeniay I. Clinical and immunological characteristics of patients with rheumatoid arthritis and periodontal disease. J Nihon Univ Sch Dent 1992;34:89-95.
20. Mercado F, Marshall RI, Klestov AC, Bartold PM. Is there a relationship between rheumatoid arthritis and periodontal disease? J Clin Periodontol 2000;27: 267-272.
21. Mercado FB, Marshall RI, Klestov AC, Bartold PM. Relationship between rheumatoid arthritis and periodontitis. J Periodontol 2001;72:779-787.
22. Lofman O, Larsson L, Toss G. Bone mineral density in diagnosis of osteoporosis: Reference population, definition of peak bone mass, and measured site determine prevalence. J Clin Densitom 2000;3:177-186.
23. Haber J, Wattles J, Crowley M, Mandell R, Joshipura K, Kent RL. Evidence for cigarette smoking as a major risk factor for periodontitis. J Periodontol 1993;64: 16-23.
24. Calsina G, Ramón JM, Echeverría JJ. Effects of smoking on periodontal tissues. J Clin Periodontol 2002;29:771-776.
25. Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 2004;83:166-169.
26. Vernal R, Chaparro A, Graumann R, Puente J, Valenzuela MA, Gamonal J. Levels of cytokine receptor activator of nuclear factor kappaB ligand in gingival crevicular fluid in untreated chronic periodontitis patients. J Periodontol 2004;75:1586-1591.
27. Lu H-K, Chen Y-L, Chang H-C, Li C-L, Kuo MY-P. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. J Periodontal Res 2006;41: 354-360.
28. Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159:1689-1699.
29. Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-Alpha-mediated joint destruction. J Clin Invest 2002;110:1419-1427.
30. Takayanagi H, Juji T, Miyazaki T, et al. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest 1999;104:137-146.
31. Nakashima T, Takayanagi H. The dynamic interplay between osteoclasts and the immune system. Arch Biochem Biophys 2008;473:166-171.
32. Henriksen K, Bollerslev J, Everts V, Karsdal MA. Osteoclast activity and subtypes as a function of physiology and pathology -Implications for future treatments of osteoporosis. Endocr Rev 2011;32:31-63.
33. Dempster DW, Lambing CL, Kostenuik PJ, Grauer A. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: A review of preclinical and clinical data. Clin Ther 2012;34:521-536.
34. Bostanci N, -Ilgenli T, Emingil G, et al. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: Implications of their relative ratio. J Clin Periodontol 2007;34:370-376.
35. Crotti T, Smith MD, Hirsch R, et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003;38:380-387.
36. Lerner UH. Inflammation-induced bone remodeling in periodontal disease and the influence of postmenopausal osteoporosis. J Dent Res 2006;85:596-607.
37. Niimoto T, Nakasa T, Ishikawa M, et al. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord 2010;11:209-220.
38. Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis MA, Miossec P. Genome-wide comparison between IL-17A-And IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol 2009;182:3112-3120.
39. Sato K. Th17 cells and rheumatoid arthritis -From the standpoint of osteoclast differentiation -. Allergol Int 2008;57:109-114.
40. Lester SR, Bain JL, Johnson RB, Serio FG. Gingival concentrations of interleukin-23 and -17 at healthy sites and at sites of clinical attachment loss. J Periodontol 2007;78:1545-1550.
41. Ohyama H, Kato-Kogoe N, Kuhara A, et al. The involvement of IL-23 and the Th17 pathway in periodontitis. J Dent Res 2009;88:633-638.
42. Honda T, Aoki Y, Takahashi N, et al. Elevated expression of IL-17 and IL-12 genes in chronic inflammatory periodontal disease. Clin Chim Acta 2008;395:137-141.
43. Cardoso CR, Garlet GP, Crippa GE, et al. Evidence of the presence of T helper type 17 cells in chronic lesions of human periodontal disease. Oral Microbiol Immunol 2009;24:1-6.
44. Vernal R, Dutzan N, Chaparro A, Puente J, Antonieta Valenzuela M, Gamonal J. Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis. J Clin Periodontol 2005;32: 383-389.
45. Yetkin Ay Z, Sutcxu R, Uskun E, Bozkurt FY, Berker E. The impact of the IL-11:IL-17 ratio on the chronic periodontitis pathogenesis: A preliminary report. Oral Dis 2009;15:93-99.
46. Trouvin AP, Goeb V. Receptor activator of nuclear factor-kB ligand and osteoprotegerin: Maintaining the balance to prevent bone loss. Clin Interv Aging 2010;5:345-354.